{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T13:21:41Z","timestamp":1790256101229,"version":"4.1.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T00:00:00Z","timestamp":1698883200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T00:00:00Z","timestamp":1698883200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["K12 DA050607"],"award-info":[{"award-number":["K12 DA050607"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"name":"University of Pittsburgh Division of General Internal Medicine"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Harm Reduct J"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The rising rates of drug use-related complications call for a paradigm shift in the care for people who use drugs. While addiction treatment and harm reduction have historically been siloed in the US, co-location of these services in office-based addiction treatment (OBAT) settings offers a more realistic and patient-centered approach. We describe a quality improvement program on integrating harm reduction kits into an urban OBAT clinic.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>After engaging appropriate stakeholders and delivering clinician and staff trainings on safer use best practices, we developed a clinical workflow for universal offering and distribution of pre-packaged kits coupled with patient-facing educational handouts. We assessed: (1) kit uptake with kit number and types distributed; and (2) implementation outcomes of feasibility, acceptability, appropriateness, and patient perceptions.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>One-month post-implementation, 28% (40\/141) of completed in-person visits had at least one kit request, and a total of 121 kits were distributed. Staff and clinicians found the program to be highly feasible, acceptable, and appropriate, and patient perceptions were positive.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Incorporating kits in OBAT settings is an important step toward increasing patient access and utilization of life-saving services. Our program uncovered a significant unmet need among our patients, suggesting that kit integration within addiction treatment can improve the standard of care for people who use drugs.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12954-023-00897-5","type":"journal-article","created":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T09:02:51Z","timestamp":1698915771000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Implementing harm reduction kits in an office-based addiction treatment program"],"prefix":"10.1186","volume":"20","author":[{"given":"Margaret","family":"Shang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brent","family":"Thiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane M.","family":"Liebschutz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin L.","family":"Kraemer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariana","family":"Freund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raagini","family":"Jawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,2]]},"reference":[{"key":"897_CR1","first-page":"1","volume":"457","author":"MR Spencer","year":"2022","unstructured":"Spencer MR, Minino AM, Warner M. Drug overdose deaths in the United States, 2001\u20132021. NCHS Data Brief. 2022;457:1\u20138.","journal-title":"NCHS Data Brief"},{"key":"897_CR2","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.drugpo.2019.01.010","volume":"71","author":"D Ciccarone","year":"2019","unstructured":"Ciccarone D. The triple wave epidemic: supply and demand drivers of the US opioid overdose crisis. Int J Drug Policy. 2019;71:183\u20138.","journal-title":"Int J Drug Policy"},{"issue":"24","key":"897_CR3","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1056\/NEJMp2303120","volume":"388","author":"R Gupta","year":"2023","unstructured":"Gupta R, Holtgrave DR, Ashburn MA. Xylazine\u2014medical and public health imperatives. N Engl J Med. 2023;388(24):2209\u201312.","journal-title":"N Engl J Med"},{"key":"897_CR4","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.drugalcdep.2016.04.009","volume":"163","author":"D Ciccarone","year":"2016","unstructured":"Ciccarone D, Unick GJ, Cohen JK, Mars SG, Rosenblum D. Nationwide increase in hospitalizations for heroin-related soft tissue infections: associations with structural market conditions. Drug Alcohol Depend. 2016;163:126\u201333.","journal-title":"Drug Alcohol Depend"},{"issue":"2","key":"897_CR5","doi-asserted-by":"publisher","first-page":"244","DOI":"10.2105\/AJPH.2019.305412","volume":"110","author":"TJ Cicero","year":"2020","unstructured":"Cicero TJ, Ellis MS, Kasper ZA. Polysubstance use: a broader understanding of substance use during the opioid crisis. Am J Public Health. 2020;110(2):244\u201350.","journal-title":"Am J Public Health"},{"issue":"1","key":"897_CR6","doi-asserted-by":"publisher","first-page":"31","DOI":"10.7326\/M18-2124","volume":"170","author":"AJ Schranz","year":"2019","unstructured":"Schranz AJ, Fleischauer A, Chu VH, Wu LT, Rosen DL. Trends in drug use-associated infective endocarditis and heart valve Surgery, 2007 to 2017: a study of statewide discharge data. Ann Intern Med. 2019;170(1):31\u201340.","journal-title":"Ann Intern Med"},{"key":"897_CR7","unstructured":"Actions Taken by the Biden-\u2060Harris Administration to Address Addiction and the Overdose Epidemic 2022. https:\/\/www.whitehouse.gov\/ondcp\/briefing-room\/2022\/08\/31\/actions-taken-by-the-biden-harris-administration-to-address-addiction-and-the-overdose-epidemic\/."},{"key":"897_CR8","unstructured":"Centers for Disease Control and Prevention. Summary of Information on the Safety and Effectiveness of Syringe Services Programs (SSPs) [updated January 11, 2023]. https:\/\/www.cdc.gov\/ssp\/syringe-services-programs-summary.html."},{"issue":"5 Suppl 1","key":"897_CR9","doi-asserted-by":"publisher","first-page":"S118","DOI":"10.1016\/j.amepre.2021.05.044","volume":"61","author":"D Broz","year":"2021","unstructured":"Broz D, Carnes N, Chapin-Bardales J, Des Jarlais DC, Handanagic S, Jones CM, et al. Syringe services programs\u2019 role in ending the HIV epidemic in the U.S.: why we cannot do it without them. Am J Prev Med. 2021;61(5 Suppl 1):S118\u201329.","journal-title":"Am J Prev Med"},{"issue":"1_suppl","key":"897_CR10","doi-asserted-by":"publisher","first-page":"128S","DOI":"10.1177\/0033354920921817","volume":"135","author":"MH Fernandez-Vina","year":"2020","unstructured":"Fernandez-Vina MH, Prood NE, Herpolsheimer A, Waimberg J, Burris S. State laws governing syringe services programs and participant syringe possession, 2014\u20132019. Public Health Rep. 2020;135(1_suppl):128S-S137.","journal-title":"Public Health Rep"},{"issue":"2","key":"897_CR11","first-page":"137","volume":"27","author":"SC Ijioma","year":"2021","unstructured":"Ijioma SC, Pontinha VM, Holdford DA, Carroll NV. Cost-effectiveness of syringe service programs, medications for opioid use disorder, and combination programs in hepatitis C harm reduction among opioid injection drug users: a public payer perspective using a decision tree. J Manag Care Spec Pharm. 2021;27(2):137\u201346.","journal-title":"J Manag Care Spec Pharm"},{"issue":"4","key":"897_CR12","doi-asserted-by":"publisher","first-page":"e237888","DOI":"10.1001\/jamanetworkopen.2023.7888","volume":"6","author":"R Jawa","year":"2023","unstructured":"Jawa R, Tin Y, Nall S, Calcaterra SL, Savinkina A, Marks LR, et al. Estimated clinical outcomes and cost-effectiveness associated with provision of addiction treatment in US primary care clinics. JAMA Netw Open. 2023;6(4):e237888.","journal-title":"JAMA Netw Open"},{"key":"897_CR13","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.jsat.2016.12.010","volume":"74","author":"ZM Weinstein","year":"2017","unstructured":"Weinstein ZM, Kim HW, Cheng DM, Quinn E, Hui D, Labelle CT, et al. Long-term retention in Office Based Opioid Treatment with buprenorphine. J Subst Abuse Treat. 2017;74:65\u201370.","journal-title":"J Subst Abuse Treat"},{"issue":"1","key":"897_CR14","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s12954-022-00676-8","volume":"19","author":"N Krawczyk","year":"2022","unstructured":"Krawczyk N, Allen ST, Schneider KE, Solomon K, Shah H, Morris M, et al. Intersecting substance use treatment and harm reduction services: exploring the characteristics and service needs of a community-based sample of people who use drugs. Harm Reduct J. 2022;19(1):95.","journal-title":"Harm Reduct J"},{"issue":"3","key":"897_CR15","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.idc.2020.06.013","volume":"34","author":"K Thakarar","year":"2020","unstructured":"Thakarar K, Nenninger K, Agmas W. Harm reduction services to prevent and treat infectious diseases in people who use drugs. Infect Dis Clin N Am. 2020;34(3):605\u201320.","journal-title":"Infect Dis Clin N Am"},{"issue":"10118","key":"897_CR16","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/S0140-6736(17)32812-X","volume":"391","author":"JD Lee","year":"2018","unstructured":"Lee JD, Nunes EV Jr, Novo P, Bachrach K, Bailey GL, Bhatt S, et al. Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial. Lancet. 2018;391(10118):309\u201318.","journal-title":"Lancet"},{"issue":"9776","key":"897_CR17","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1016\/S0140-6736(11)60358-9","volume":"377","author":"E Krupitsky","year":"2011","unstructured":"Krupitsky E, Nunes EV, Ling W, Illeperuma A, Gastfriend DR, Silverman BL. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial. Lancet. 2011;377(9776):1506\u201313.","journal-title":"Lancet"},{"issue":"3","key":"897_CR18","doi-asserted-by":"publisher","first-page":"137","DOI":"10.7326\/M17-3107","volume":"169","author":"MR Larochelle","year":"2018","unstructured":"Larochelle MR, Bernson D, Land T, Stopka TJ, Wang N, Xuan Z, et al. Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: a cohort study. Ann Intern Med. 2018;169(3):137\u201345.","journal-title":"Ann Intern Med"},{"key":"897_CR19","first-page":"CD002209","volume":"2","author":"RP Mattick","year":"2003","unstructured":"Mattick RP, Breen C, Kimber J, Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev. 2003;2:CD002209.","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"897_CR20","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.drugpo.2010.09.007","volume":"22","author":"J Neale","year":"2011","unstructured":"Neale J, Nettleton S, Pickering L. What is the role of harm reduction when drug users say they want abstinence? Int J Drug Policy. 2011;22(3):189\u201393.","journal-title":"Int J Drug Policy"},{"key":"897_CR21","doi-asserted-by":"publisher","first-page":"102934","DOI":"10.1016\/j.drugpo.2020.102934","volume":"85","author":"PK Valente","year":"2020","unstructured":"Valente PK, Bazzi AR, Childs E, Salhaney P, Earlywine J, Olson J, et al. Patterns, contexts, and motivations for polysubstance use among people who inject drugs in non-urban settings in the US Northeast. Int J Drug Policy. 2020;85:102934.","journal-title":"Int J Drug Policy"},{"key":"897_CR22","unstructured":"National Health Care for the Homeless Council. Health Centers and Syringe Services Programs 2023. https:\/\/nhchc.org\/wp-content\/uploads\/2023\/06\/Health-Centers-SSPs-Final.pdf."},{"issue":"10","key":"897_CR23","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.2105\/AJPH.2018.304600","volume":"108","author":"M Miskovic","year":"2018","unstructured":"Miskovic M, Chan Carusone S, Guta A, O\u2019Leary B, dePrinse K, Strike C. Distribution of harm reduction kits in a specialty HIV hospital. Am J Public Health. 2018;108(10):1363\u20135.","journal-title":"Am J Public Health"},{"key":"897_CR24","doi-asserted-by":"publisher","first-page":"109608","DOI":"10.1016\/j.drugalcdep.2022.109608","volume":"239","author":"S Nolan","year":"2022","unstructured":"Nolan S, Kelian S, Kerr T, Young S, Malmgren I, Ghafari C, et al. Harm reduction in the hospital: an overdose prevention site (OPS) at a Canadian hospital. Drug Alcohol Depend. 2022;239:109608.","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"897_CR25","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s12954-022-00596-7","volume":"19","author":"E Dogherty","year":"2022","unstructured":"Dogherty E, Patterson C, Gagnon M, Harrison S, Chase J, Boerstler J, et al. Implementation of a nurse-led overdose prevention site in a hospital setting: lessons learned from St. Paul\u2019s Hospital, Vancouver, Canada. Harm Reduct J. 2022;19(1):13.","journal-title":"Harm Reduct J"},{"issue":"12","key":"897_CR26","doi-asserted-by":"publisher","first-page":"3810","DOI":"10.1007\/s11606-021-06904-4","volume":"36","author":"JL Taylor","year":"2021","unstructured":"Taylor JL, Johnson S, Cruz R, Gray JR, Schiff D, Bagley SM. Integrating harm reduction into outpatient opioid use disorder treatment settings: harm reduction in outpatient addiction treatment. J Gen Intern Med. 2021;36(12):3810\u20139.","journal-title":"J Gen Intern Med"},{"key":"897_CR27","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1007\/s11606-023-08183-7","volume":"38","author":"A Chatterjee","year":"2023","unstructured":"Chatterjee A, Bannister M, Hill LG, Davis CS. Prescribing syringes to people who inject drugs: advancing harm reduction in primary care. J Gen Intern Med. 2023;38:1980\u20133.","journal-title":"J Gen Intern Med"},{"issue":"2","key":"897_CR28","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s10488-010-0319-7","volume":"38","author":"E Proctor","year":"2011","unstructured":"Proctor E, Silmere H, Raghavan R, Hovmand P, Aarons G, Bunger A, et al. Outcomes for implementation research: conceptual distinctions, measurement challenges, and research agenda. Adm Policy Ment Health. 2011;38(2):65\u201376.","journal-title":"Adm Policy Ment Health"},{"issue":"9","key":"897_CR29","doi-asserted-by":"publisher","first-page":"e067219","DOI":"10.1136\/bmjopen-2022-067219","volume":"12","author":"ES Kay","year":"2022","unstructured":"Kay ES, Creasy S, Batey DS, Coulter R, Egan JE, Fisk S, et al. Impact of harm reduction care in HIV clinical settings on stigma and health outcomes for people with HIV who use drugs: study protocol for a mixed-methods, multisite, observational study. BMJ Open. 2022;12(9):e067219.","journal-title":"BMJ Open"},{"issue":"1","key":"897_CR30","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s12954-022-00594-9","volume":"19","author":"R Perera","year":"2022","unstructured":"Perera R, Stephan L, Appa A, Giuliano R, Hoffman R, Lum P, et al. Meeting people where they are: implementing hospital-based substance use harm reduction. Harm Reduct J. 2022;19(1):14.","journal-title":"Harm Reduct J"},{"issue":"12","key":"897_CR31","doi-asserted-by":"publisher","first-page":"3079","DOI":"10.1111\/add.15959","volume":"117","author":"M Burns","year":"2022","unstructured":"Burns M, Tang L, Chang CH, Kim JY, Ahrens K, Allen L, et al. Duration of medication treatment for opioid-use disorder and risk of overdose among Medicaid enrollees in 11 states: a retrospective cohort study. Addiction. 2022;117(12):3079\u201388.","journal-title":"Addiction"},{"issue":"11","key":"897_CR32","doi-asserted-by":"publisher","first-page":"e1002969","DOI":"10.1371\/journal.pmed.1002969","volume":"16","author":"AC Tsai","year":"2019","unstructured":"Tsai AC, Kiang MV, Barnett ML, Beletsky L, Keyes KM, McGinty EE, et al. Stigma as a fundamental hindrance to the United States opioid overdose crisis response. PLoS Med. 2019;16(11):e1002969.","journal-title":"PLoS Med"},{"issue":"4","key":"897_CR33","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1080\/08897077.2019.1671942","volume":"41","author":"R Simon","year":"2020","unstructured":"Simon R, Snow R, Wakeman S. Understanding why patients with substance use disorders leave the hospital against medical advice: a qualitative study. Subst Abus. 2020;41(4):519\u201325.","journal-title":"Subst Abus"},{"issue":"3","key":"897_CR34","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1080\/08897077.2021.1932697","volume":"42","author":"R Jawa","year":"2021","unstructured":"Jawa R, Saravanan N, Burrowes SAB, Demers L. A call for training graduate medical students on harm reduction for people who inject drugs. Subst Abus. 2021;42(3):266\u20138.","journal-title":"Subst Abus"},{"issue":"1","key":"897_CR35","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s12954-017-0196-4","volume":"14","author":"M Hawk","year":"2017","unstructured":"Hawk M, Coulter RWS, Egan JE, Fisk S, Reuel Friedman M, Tula M, et al. Harm reduction principles for healthcare settings. Harm Reduct J. 2017;14(1):70.","journal-title":"Harm Reduct J"},{"issue":"1","key":"897_CR36","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s12954-020-00452-6","volume":"17","author":"A Davitadze","year":"2020","unstructured":"Davitadze A, Meylakhs P, Lakhov A, King EJ. Harm reduction via online platforms for people who use drugs in Russia: a qualitative analysis of web outreach work. Harm Reduct J. 2020;17(1):98.","journal-title":"Harm Reduct J"},{"issue":"1","key":"897_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12954-023-00732-x","volume":"20","author":"M Torres-Leguizamon","year":"2023","unstructured":"Torres-Leguizamon M, Favaro J, Coello D, Reynaud EG, Nefau T, Duplessy C. Remote harm reduction services are key solutions to reduce the impact of COVID-19-like crises on people who use drugs: evidence from two independent structures in France and in the USA. Harm Reduct J. 2023;20(1):1.","journal-title":"Harm Reduct J"},{"issue":"11","key":"897_CR38","doi-asserted-by":"publisher","first-page":"ofaa503","DOI":"10.1093\/ofid\/ofaa503","volume":"7","author":"AM Peckham","year":"2020","unstructured":"Peckham AM, Young EH. Opportunities to offer harm reduction to people who inject drugs during infectious disease encounters: narrative review. Open Forum Infect Dis. 2020;7(11):ofaa503.","journal-title":"Open Forum Infect Dis"},{"issue":"6","key":"897_CR39","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1111\/add.14914","volume":"115","author":"S Imtiaz","year":"2020","unstructured":"Imtiaz S, Strike C, Elton-Marshall T, Rehm J. Safer smoking kits for methamphetamine consumption. Addiction. 2020;115(6):1189\u201390.","journal-title":"Addiction"},{"issue":"4","key":"897_CR40","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.drugpo.2011.05.005","volume":"22","author":"A Ivsins","year":"2011","unstructured":"Ivsins A, Roth E, Nakamura N, Krajden M, Fischer B. Uptake, benefits of and barriers to safer crack use kit (SCUK) distribution programmes in Victoria, Canada\u2014a qualitative exploration. Int J Drug Policy. 2011;22(4):292\u2013300.","journal-title":"Int J Drug Policy"},{"issue":"2","key":"897_CR41","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1097\/AOG.0000000000001507","volume":"128","author":"N Fernandez","year":"2016","unstructured":"Fernandez N, Towers CV, Wolfe L, Hennessy MD, Weitz B, Porter S. Sharing of snorting straws and hepatitis C virus infection in pregnant women. Obstet Gynecol. 2016;128(2):234\u20137.","journal-title":"Obstet Gynecol"},{"key":"897_CR42","unstructured":"NEXT Distro. Rectal Administration. https:\/\/nextdistro.org\/resources-collection\/rectal-administration-booty-bumping-boofing-plugging."},{"issue":"1","key":"897_CR43","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.mcna.2021.09.002","volume":"106","author":"CA Chan","year":"2022","unstructured":"Chan CA, Canver B, McNeil R, Sue KL. Harm Reduction in Health Care Settings. Med Clin North Am. 2022;106(1):201\u201317.","journal-title":"Med Clin North Am"},{"key":"897_CR44","unstructured":"Commonwealth of Pennsylvania. The Controlled Substance, Drug, Device and Cosmetic Act [ ]. https:\/\/www.legis.state.pa.us\/WU01\/LI\/LI\/US\/HTM\/1972\/0\/0064..HTM."}],"container-title":["Harm Reduction Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-023-00897-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12954-023-00897-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-023-00897-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T09:06:11Z","timestamp":1698915971000},"score":1,"resource":{"primary":{"URL":"https:\/\/harmreductionjournal.biomedcentral.com\/articles\/10.1186\/s12954-023-00897-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,2]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["897"],"URL":"https:\/\/doi.org\/10.1186\/s12954-023-00897-5","relation":{},"ISSN":["1477-7517"],"issn-type":[{"value":"1477-7517","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,2]]},"assertion":[{"value":"21 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"163"}}